Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 15, 2022 17:30 ET | Source: Hagens Berman Sobol Shapiro LLP

RETA 3-DAY DEADLINE ALERT: Hagens Berman, National Trial Attorneys, Encourages Reata Pharmaceuticals (RETA) Investors with Losses to Contact Firm’s Attorneys About Opportunity to Lead Securities Fraud Action

SAN FRANCISCO, Feb. 15, 2022 (GLOBE NEWSWIRE) -- Hagens Berman urges Reata Pharmaceuticals, Inc. (NASDAQ: RETA) investors with significant losses to submit your losses now. A securities fraud...
February 15, 2022 17:19 ET | Source: Faruqi & Faruqi LLP

REATA DEADLINE ALERT: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Reata To Contact Him Directly To Discuss Their Options

NEW YORK, Feb. 15, 2022 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Reata Pharmaceuticals, Inc. (“Reata” or the...
February 10, 2022 09:35 ET | Source: Hagens Berman Sobol Shapiro LLP

RETA 8-DAY DEADLINE ALERT: Hagens Berman, National Trial Attorneys, Encourages Reata Pharmaceuticals (RETA) Investors with Losses to Contact Firm’s Attorneys Before Feb. 18th Deadline

SAN FRANCISCO, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Hagens Berman urges Reata Pharmaceuticals, Inc. (NASDAQ: RETA) investors with significant losses to submit your losses now. A securities fraud class...
February 05, 2022 09:46 ET | Source: Hagens Berman Sobol Shapiro LLP

RETA 13-DAY ALERT: Hagens Berman, National Trial Attorneys, Encourages Reata Pharmaceuticals (RETA) Investors with Losses to Contact Firm’s Attorneys Before Feb. 18th Deadline in Securities Fraud Case

SAN FRANCISCO, Feb. 05, 2022 (GLOBE NEWSWIRE) -- Hagens Berman urges Reata Pharmaceuticals, Inc. (NASDAQ: RETA) investors with significant losses to submit your losses now. A securities fraud class...
January 31, 2022 12:18 ET | Source: Hagens Berman Sobol Shapiro LLP

RETA INVESTOR NOTICE: Hagens Berman, National Trial Attorneys, Encourages Reata Pharmaceuticals (RETA) Investors with Losses to Contact Firm’s Attorneys, Securities Class Action Pending

SAN FRANCISCO, Jan. 31, 2022 (GLOBE NEWSWIRE) -- Hagens Berman urges Reata Pharmaceuticals, Inc. (NASDAQ: RETA) investors with significant losses to submit your losses now. A securities fraud...
January 24, 2022 09:40 ET | Source: Hagens Berman Sobol Shapiro LLP

RETA INVESTOR ALERT: Hagens Berman, National Trial Attorneys, Encourages Reata Pharmaceuticals (RETA) Investors with Losses to Contact Firm’s Attorneys, Securities Class Action Pending

SAN FRANCISCO, Jan. 24, 2022 (GLOBE NEWSWIRE) -- Hagens Berman urges Reata Pharmaceuticals, Inc. (NASDAQ: RETA) investors with significant losses to submit your losses now. A securities fraud...
January 18, 2022 14:01 ET | Source: Hagens Berman Sobol Shapiro LLP

RETA INVESTOR ALERT: Hagens Berman, National Trial Attorneys, Encourages Reata Pharmaceuticals (RETA) Investors to Contact Firm’s Attorneys, Securities Class Action Filed

SAN FRANCISCO, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Hagens Berman urges Reata Pharmaceuticals, Inc. (NASDAQ: RETA) investors with significant losses to submit your losses now. A securities fraud...
January 13, 2022 14:58 ET | Source: Hagens Berman Sobol Shapiro LLP

RETA DEADLINE ALERT: Hagens Berman, National Trial Attorneys, Encourages Reata Pharmaceuticals (RETA) Investors to Contact Firm’s Attorneys, Securities Class Action Pending

SAN FRANCISCO, Jan. 13, 2022 (GLOBE NEWSWIRE) -- Hagens Berman urges Reata Pharmaceuticals, Inc. (NASDAQ: RETA) investors with significant losses to submit your losses now. A securities fraud...
January 08, 2022 13:05 ET | Source: Hagens Berman Sobol Shapiro LLP

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Reata Pharmaceuticals (RETA) Investors to Contact Firm’s Attorneys, Deadline Approaching in Securities Class Action

SAN FRANCISCO, Jan. 08, 2022 (GLOBE NEWSWIRE) -- Hagens Berman urges Reata Pharmaceuticals, Inc. (NASDAQ: RETA) investors with significant losses to submit your losses now. A securities fraud class...
January 03, 2022 13:42 ET | Source: Hagens Berman Sobol Shapiro LLP

RETA INVESTOR FRAUD: Hagens Berman, National Trial Attorneys, Encourages Reata Pharmaceuticals, Inc. (RETA) Investors to Contact Firm’s Attorneys, Securities Fraud Class Action Pending

SAN FRANCISCO, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Hagens Berman urges Reata Pharmaceuticals, Inc. (NASDAQ: RETA) investors with significant losses to submit your losses now. A securities fraud class...